POLYMER-BASED INTERFACE TARGETING INFLAMMATION IN ULCERATIVE COLITIS

A major hurdle in the treatment of inflammatory bowel disease (IBD) is the lack of effective drug carriers that can precisely deliver the required amount of drug to the sites of inflammation. Available therapies have limited efficacy or severe side effects, largely because of the low concentration of active drugs at the disease sites and non-specific systemic absorption of the administered drugs. Drug delivery targeting the sites of intestinal inflammation offers an approach to maximize therapeutic efficacy while minimizing adverse side effects.